TD Private Client Wealth LLC Sells 2,292 Shares of Agilent Technologies, Inc. (NYSE:A)

TD Private Client Wealth LLC decreased its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 36.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,996 shares of the medical research company's stock after selling 2,292 shares during the quarter. TD Private Client Wealth LLC's holdings in Agilent Technologies were worth $467,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Redwood Park Advisors LLC purchased a new stake in shares of Agilent Technologies in the fourth quarter worth $27,000. Lee Danner & Bass Inc. purchased a new stake in shares of Agilent Technologies in the fourth quarter worth $29,000. Sunbelt Securities Inc. grew its stake in shares of Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock worth $30,000 after acquiring an additional 192 shares during the last quarter. Whipplewood Advisors LLC grew its stake in shares of Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock worth $29,000 after acquiring an additional 186 shares during the last quarter. Finally, Wood Tarver Financial Group LLC purchased a new stake in shares of Agilent Technologies in the fourth quarter worth $34,000.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Agilent Technologies Trading Up 2.4%

Shares of NYSE:A opened at $124.18 on Friday. The stock has a market capitalization of $35.28 billion, a price-to-earnings ratio of 30.66, a PEG ratio of 3.68 and a beta of 1.23. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09. The stock's 50-day simple moving average is $114.94 and its two-hundred day simple moving average is $122.93. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last announced its earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.05. The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. The business's revenue for the quarter was up 6.0% on a year-over-year basis. During the same period last year, the firm posted $1.22 earnings per share. Analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be given a $0.248 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.99 annualized dividend and a yield of 0.80%. Agilent Technologies's payout ratio is 24.44%.

Analyst Ratings Changes

A number of research firms have recently commented on A. Robert W. Baird cut their target price on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research note on Thursday, May 22nd. Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. UBS Group cut their target price on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research note on Thursday, May 29th. JPMorgan Chase & Co. dropped their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a research report on Thursday, May 29th. Finally, Leerink Partners increased their price objective on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Friday, May 30th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $139.77.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.